Top

Published in:

01-12-2019 | Breast Cancer | Original Article

Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer

Authors: In Hye Song, Young-Ae Kim, Hyeonjin Lee, Hye Seon Park, In Ah Park, Chan Kyu Sim, Myeong Sup Lee, Gyungyub Gong, Hee Jin Lee

Published in: Immunologic Research | Issue 6/2019

Abstract

The expression of major histocompatibility complex class I (MHC I) in tumor cells is regulated by interferon signaling, and it is an important factor in the efficacy of cytotoxic T cell–dependent immunotherapy. To determine the impact of immune cells in MHC I expression on tumor cells, we compared the expression of MHC I in tumor cells derived from primary breast cancers and patient-derived xenograft (PDX) models. MHC I and myxovirus resistance gene A (MxA) expression were analyzed using immunohistochemistry in 23 cases of tumor tissue and corresponding primary and secondary PDXs. The median H score of MHC I was 210 (0–300) in patient tumor tissues, 197.5 (0–300) in primary PDX tumors, and 157.5 (5–300) in secondary PDX tumors. Cases were divided into four groups based on the difference in MHC I expression between the patient tumor tissues and secondary PDXs. Eleven cases constituted the high MHC I group, four constituted the low MHC I group, six comprised the decreased MHC I group, and two comprised the increased MHC I group. MHC I and MxA expressions in each tumor were weakly correlated within patients’ tumors, while strongly correlated within PDX models. Retained or altered expression of MHC I in breast cancer PDXs reveals the presence of intrinsic and extrinsic interferon signaling pathways in tumor cells. Thus, considering MHC I expression in PDX is important when using PDX models to evaluate the efficacy of cancer immunotherapy in a preclinical setting.

Available only for authorised users

Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 2018. https://doi.org/10.1016/j.drudis.2018.02.012.CrossRefPubMed

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8. https://doi.org/10.1186/s40425-018-0316-z.CrossRefPubMedPubMedCentral

Chae YK, Oh MS, Giles FJ. Molecular biomarkers of primary and acquired resistance to T-cell-mediated immunotherapy in cancer: landscape, clinical implications, and future directions. Oncologist. 2018;23(4):410–21. https://doi.org/10.1634/theoncologist.2017-0354.CrossRefPubMed

Agrawal S, Kishore MC. MHC class I gene expression and regulation. J Hematother Stem Cell Res. 2000;9(6):795–812. https://doi.org/10.1089/152581600750062237.CrossRefPubMed

Silginer M, Nagy S, Happold C, Schneider H, Weller M, Roth P. Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. Neuro-Oncology. 2017;19(10):1338–49. https://doi.org/10.1093/neuonc/nox051.CrossRefPubMedPubMedCentral

Hu JL, Hua YJ, Chen Y, Yu B, Gao S. Structural analysis of tumor-related single amino acid mutations in human MxA protein. Chin J Cancer. 2015;34(12):583–93. https://doi.org/10.1186/s40880-015-0055-1.CrossRefPubMed

Lee HJ, Song IH, Park IA, Heo SH, Kim YA, Ahn JH, et al. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget. 2016;7(21):30119–32. https://doi.org/10.18632/oncotarget.8798.CrossRefPubMedPubMedCentral

Kim YA, Lee HJ, Heo SH, Park HS, Park SY, Bang W, et al. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. Breast Cancer Res Treat. 2016;156(3):597–606. https://doi.org/10.1007/s10549-016-3786-z.CrossRefPubMed

Whittle JR, Lewis MT, Lindeman GJ, Visvader JE. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015;17:17. https://doi.org/10.1186/s13058-015-0523-1.CrossRefPubMedPubMedCentral

10.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–71. https://doi.org/10.1093/annonc/mdu450.CrossRefPubMed

11.

Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–81. https://doi.org/10.1200/JCO.1999.17.5.1474.CrossRefPubMed

12.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, College of American P (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138 (2):241–256. doi:https://doi.org/10.5858/arpa.2013-0953-SA.CrossRef

13.

WHO classification of tumours of the breast (2012). 4th. International Agency for Research on Cancer

14.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. https://doi.org/10.1158/2159-8290.CD-12-0095.CrossRefPubMed

15.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci signal. 2013;6(269):pl1-pl1. https://doi.org/10.1126/scisignal.2004088.CrossRef

16.

Fleming JM, Miller TC, Meyer MJ, Ginsburg E, Vonderhaar BK. Local regulation of human breast xenograft models. J Cell Physiol. 2010;224(3):795–806. https://doi.org/10.1002/jcp.22190.CrossRefPubMedPubMedCentral

17.

Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49(11):1567–75. https://doi.org/10.1038/ng.3967.CrossRefPubMedPubMedCentral

18.

Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2015;518(7539):422–6. https://doi.org/10.1038/nature13952.CrossRefPubMed

19.

Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol. 2017;28(10):2595–605. https://doi.org/10.1093/annonc/mdx416.CrossRefPubMedPubMedCentral

20.

Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, et al. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology. 2016;18(3):368–78. https://doi.org/10.1093/neuonc/nov153.CrossRefPubMed

21.

Jespersen H, Lindberg MF, Donia M, Soderberg EMV, Andersen R, Keller U, et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat Commun. 2017;8(1):707. https://doi.org/10.1038/s41467-017-00786-z.CrossRefPubMedPubMedCentral

22.

De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized mice for the study of immuno-oncology. Trends Immunol. 2018;39(9):748–63. https://doi.org/10.1016/j.it.2018.07.001.CrossRef

23.

Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. Journal for ImmunoTherapy of Cancer. 2019;7(1):37. https://doi.org/10.1186/s40425-019-0518-z.CrossRefPubMedPubMedCentral

24.

Li H, Zhu Y, Tang X, Li J, Li Y, Zhong Z, et al. Integrated analysis of transcriptome in cancer patient-derived xenografts. PLoS One. 2015;10(5):e0124780. https://doi.org/10.1371/journal.pone.0124780.CrossRefPubMedPubMedCentral

25.

Wang D, Li JR, Zhang YH, Chen L, Huang T, Cai YD. Identification of differentially expressed genes between original breast cancer and xenograft using machine learning algorithms. Genes (Basel). 2018;9(3). https://doi.org/10.3390/genes9030155.CrossRefPubMedCentral

26.

Kaur G, Batra S. Emerging role of immunoproteasomes in pathophysiology. Immunol Cell Biol. 2016;94(9):812–20. https://doi.org/10.1038/icb.2016.50.CrossRefPubMed

27.

Gresser I, Maury C, Brouty-Boye D. Mechanism of the antitumour effect of interferon in mice. Nature. 1972;239(5368):167–8.CrossRefPubMed

28.

Brockwell NK, Parker BS. Tumor inherent interferons: impact on immune reactivity and immunotherapy. Cytokine. 2018. https://doi.org/10.1016/j.cyto.2018.04.006.CrossRefPubMed

29.

Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, et al. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy. Journal of immunology (Baltimore, Md : 1950). 2014;192(12):5821–9. https://doi.org/10.4049/jimmunol.1400404.CrossRef

30.

Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012;72(20):5188–97. https://doi.org/10.1158/0008-5472.CAN-11-3468.CrossRefPubMed

31.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301–9. https://doi.org/10.1038/nm.3708.CrossRefPubMed

Title: Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer
Authors: In Hye Song
Young-Ae Kim
Hyeonjin Lee
Hye Seon Park
In Ah Park
Chan Kyu Sim
Myeong Sup Lee
Gyungyub Gong
Hee Jin Lee
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Interferon
Cancer Immunotherapy
Published in: Immunologic Research / Issue 6/2019
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-019-09109-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers

Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I–deficient breast cancer cells

CD226 attenuates Treg suppressive capacity via CTLA-4 and TIGIT during EAE

Autoantibodies against P29ING4 are associated with complex regional pain syndrome

A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome